ProCan Technologies

ProCan® de-risks, accelerates and decreases the cost of oncology clinical trials.

[ProCan Technologies @ProCanTech]

A reminder that this is your last chance to register for the ProCan® Technologies live webinar “Unlocking Proteomics for Smarter Antibody–Drug Conjugate (ADC) Development’’ being held on Thursday 26th June which features Prof Roger Reddel. Register here: https://t.co/ncTHGwBNXg

[ProCan Technologies @ProCanTech]

🧪Speakers:
– Prof Roger Reddel (ProCan / @CMRI_AUS)
– Dr Jia (Jenny) Liu (St Vincent’s Hospital)
– Prof Paul Waring (@UniMelb / TissuPath)
– Moderator: Matthew Britland (MedWise Consulting)

📎 Register to attend (no cost):
https://t.co/ncTHGwClMO

[ProCan Technologies @ProCanTech]

Thursday 26 June | 4–5:15 PM AEST
ProCan® Technologies is hosting a live, expert-led webinar exploring how mass spectrometry-based proteomics is being applied to improve Antibody–Drug Conjugate development—from target discovery to clinical evaluation and patient stratification.

[ProCan Technologies @ProCanTech]

🧬Key Topics:
• Translational and clinical challenges in ADC development
• Gaps in current biomarker strategies and why proteomics matters
• How the ProCan ADC Panel is being applied across the development pipeline
• Perspectives from pathology, oncology, and industry experts

[ProCan Technologies @ProCanTech]

ProCan Technologies Limited has launched the new TargetQuant™ ADC Panel at @IAmBiotech #BIO2025 in Boston today - a multi-protein target screening panel designed to improve oncology research and clinical trial outcomes globally. Read more: https://t.co/xHPYljCVWU #ProCanTech

[ProCan Technologies @ProCanTech]

A global collaboration with @InescID has led to #MOSA, a groundbreaking #AI method transforming #cancer research! MOSA fills gaps in multi-omic data, boosting datasets by 32.7% for 1,500+ cancer cell lines. Learn more: https://t.co/T6YA7rMFR0